|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2011-1-5
|
|
pubmed:abstractText |
Whether and to what extent germline mutations in the BRCA1 and BRCA2 genes increase the risk for developing uterine serous carcinoma (USC) remain controversial. We assessed the rate of the 3 predominant BRCA1/2 mutations in Jewish patients with USC and the relevance of carrier status to clinicopathological features and survival.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1525-1438
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
20
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1148-53
|
|
pubmed:meshHeading |
pubmed-meshheading:21206239-Aged,
pubmed-meshheading:21206239-Aged, 80 and over,
pubmed-meshheading:21206239-Antineoplastic Agents,
pubmed-meshheading:21206239-BRCA1 Protein,
pubmed-meshheading:21206239-BRCA2 Protein,
pubmed-meshheading:21206239-Breast Neoplasms,
pubmed-meshheading:21206239-Chemotherapy, Adjuvant,
pubmed-meshheading:21206239-Cystadenocarcinoma, Serous,
pubmed-meshheading:21206239-Female,
pubmed-meshheading:21206239-Genetic Predisposition to Disease,
pubmed-meshheading:21206239-Germ-Line Mutation,
pubmed-meshheading:21206239-Humans,
pubmed-meshheading:21206239-Jews,
pubmed-meshheading:21206239-Middle Aged,
pubmed-meshheading:21206239-Neoplasm Staging,
pubmed-meshheading:21206239-Ovarian Neoplasms,
pubmed-meshheading:21206239-Prognosis,
pubmed-meshheading:21206239-Retrospective Studies,
pubmed-meshheading:21206239-Survival Rate,
pubmed-meshheading:21206239-Uterine Neoplasms
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
BRCA1/2 germline mutations in Jewish patients with uterine serous carcinoma.
|
|
pubmed:affiliation |
Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, Meir Medical Center, Kfar Saba, Israel. ilan.bruchim@clalit.org.il
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
